Vaxart (VXRT) Receiving Somewhat Negative Press Coverage, Analysis Shows

News articles about Vaxart (NASDAQ:VXRT) have trended somewhat negative recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vaxart earned a media sentiment score of -0.06 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.5347214764946 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Separately, ValuEngine upgraded shares of Vaxart from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

VXRT stock opened at $5.06 on Friday. Vaxart has a 12-month low of $4.73 and a 12-month high of $11.88.

Vaxart (NASDAQ:VXRT) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported ($0.09) EPS for the quarter. The firm had revenue of $2.70 million during the quarter. Vaxart had a negative return on equity of 112.43% and a negative net margin of 243.59%.

TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at

Vaxart Company Profile

Vaxart, Inc, formerly Aviragen Therapeutics, Inc, is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.

Leave a Reply